Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Jan 28;8:577125. doi: 10.3389/fcell.2020.577125

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2021 Luo, Chen, Zhang, Huang, Zhao, Zhao, Li, Zhou, Liu, Cai and Bi.

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

Immune prognostic model (IPM) stratifies a refractory colorectal liver metastasis (CRLM) subtype in a real-world cohort (CICAMS CRLM cohort). (A) A difference trend in PFS was found between the high- and low-risk group although without significance (P = 0.216). (B) K–M survival curves of three IPM genes. (C–H) When applied for subcategories of patients with commonly known high-recurrence risk [liver metastasis number >3, high preoperative carcinoembryonic antigen (CEA), and non-R0 resection] at the time of diagnosis, the IPM risk score was predictive of significantly different PFS (P < 0.05). (I) IPM risk score was significantly higher in patients with more than 2 liver segments suffered (P = 0.024). (J) The relation between IPM risk score and Chemotherapy response, and non-response group tends to have a higher IPM risk score (P = 0.056).